Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $876.61M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.47M
Average 0.33M
Returns on capital
Aktis Oncology, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
43.6%
avg 62.2%
ROIC
-31.8%
avg -23.2%
ROA
-24.1%
avg -18.5%
Analysis
ROE is currently the strongest return metric at 43.6% versus its period average of 62.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Matthew Roden | President, CEO & Director | USD 914.68K | — | — | — |
Akos Czibere | Chief Medical Officer | USD 676.93K | 48 | 0 | <0.01% |
Paul L. Feldman | Chief Scientific Officer | USD 642.42K | 64 | — | — |
Shulamit Ron-Bigger | Chief Operating Officer | USD 536.71K | 45 | 0 | <0.01% |
Patrick A. Baeuerle | Co-Founder & Member of Scientific Advisory Board | — | 68 | — | — |
Tyler Benedum | Chief Technical Officer | — | 49 | — | — |
Carlos Rodriguez | Executive Director of Corporate Development | — | — | — | — |
Kyle D. Kuvalanka | Chief Financial Officer | — | 58 | — | — |
Todd Foley | Co-Founder & Chairman | — | 54 | — | — |
Dasa Lipovsek | VP & Head of Lead Discovery | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 23, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
11
$3.23M
Net Transaction Value
−$3.23M
Net selling
Most Active
Czibere Akos
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 23, 26Sep 23, 2026 | Czibere Akos Direct | Sell | $103K$102,972.78 |
| Sep 23, 26Sep 23, 2026 | Czibere Akos Direct | Sell | $155.6K$155,648.21 |
| Jul 20, 26Jul 20, 2026 | Herrmann Ken Direct | Sell | $86.1K$86,115.07 |
| Jul 20, 26Jul 20, 2026 | Herrmann Ken Direct | Sell | $33.2K$33,158.97 |
| Jul 17, 26Jul 17, 2026 | Herrmann Ken Direct | Sell | $77.3K$77,258.54 |
| Jul 8, 26Jul 8, 2026 | Ron-Bigger Shulamit Direct | Sell | $428.7K$428,680.86 |
| Jul 8, 26Jul 8, 2026 | Ron-Bigger Shulamit Direct | Sell | $838.1K$838,137.00 |
| Jul 8, 26Jul 8, 2026 | Ron-Bigger Shulamit Direct | Sell | $120.7K$120,739.92 |
| Jul 8, 26Jul 8, 2026 | Czibere Akos Direct | Sell | $401.5K$401,484.04 |
| Jul 8, 26Jul 8, 2026 | Czibere Akos Direct | Sell | $861.7K$861,735.29 |
1–10 of 11
Summary
Insiders reported 0 buys worth $0.00 and 11 sells worth $3.23M over the last 12 months. That adds up to net selling of $3.23M. Czibere Akos was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +70.9% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +70.9% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Aktis Oncology, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about AKTS's management, answered from reported figures.
Who manages AKTS?
Aktis Oncology, Inc. (AKTS) lists 10 active executives. The top listed executive is Akos Czibere, Chief Medical Officer.
Are AKTS insiders buying or selling?
Recent insider activity shows net selling of $3.23M.
Continue the stock analysis
Jump to another research area for this company.